For project outputs (e.g. abstracts, presentations, newsletters) and more information please visit our website:

www.integrate-hta.eu

or contact us at

info@integrate-hta.eu

Integrated health technology assessment for the evaluation of complex technologies

This project is co-funded by the European Union
The number of people that suffer from one or more chronic diseases is rapidly increasing around the globe. To adequately address this issue, complex health technologies, such as disease management programs or specialized palliative care services, are needed.

Health technology assessment (HTA) is defined as “the systematic evaluation of properties, effects, and/or impacts of health technology. It may address the direct, intended consequences of technologies as well as indirect, unintended consequences. Its main purpose is to inform decision making in policy and practice.”

Despite considerable achievements in recent years, contemporary HTA is not adequately equipped to assess complex technologies.

The INTEGRATE-HTA project aims to develop concepts and methods for a comprehensive, patient-centred, integrated (as opposed to simultaneous, but independent) assessment of complex technologies that enable the assessment of:

- effectiveness and economic, socio-cultural, ethical, and legal issues,
- patient preferences and patient-specific moderators of treatment,
- context, setting, and implementation.

INTEGRATE-HTA will provide methodological guidance for the assessment of complex health technologies. We currently:

- have established stakeholder advisory panels (e.g. patients, carers, and health professionals) in all partner countries and in Poland and Lithuania;
- have developed logic model templates to provide a concise graphical overview of the complex concepts of palliative care (case);
- test draft guidances for assessing the effectiveness, socio-cultural, ethical, economic, and legal issues, patient preferences, the context and implementation of the technology, as well as integration of these issues.

**TARGET AUDIENCES**

The findings of the project will inform HTA networks, national and regional HTA agencies, researchers, World Health Organization, the Cochrane Collaboration, the Campbell Collaboration, international and national health policy-makers, healthcare professionals, patients, insurers, industry, and the public.

**TIMELINE AND FUNDING**

The project runs from January 2013 until December 2015. The project is co-funded by the European Union under the Seventh Framework Programme (FP7-Health-2012-Innovation); grant agreement number 306141.

<DISCLAIMER: The sole responsibility for the content of this flyer lies with the authors. It does not necessarily reflect the opinion of the European Union. The European Commission is not responsible for any use that may be made of the information contained therein.>